67 related articles for article (PubMed ID: 20941746)
1. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients.
Ulukaya E; Acilan C; Yilmaz M; Yilmaztepe-Oral A; Ari F; Zik B; Ursavas A; Tokullugil AH
Cell Biochem Funct; 2010 Oct; 28(7):565-70. PubMed ID: 20941746
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
7. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Ugurel S; Rappl G; Tilgen W; Reinhold U
Clin Cancer Res; 2001 May; 7(5):1282-6. PubMed ID: 11350895
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
10. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
12. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
Chen P; Li J; Ge LP; Dai CH; Li XQ
Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
[TBL] [Abstract][Full Text] [Related]
14. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
[TBL] [Abstract][Full Text] [Related]
15. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble Fas level for detection and staging of prostate cancer.
Furuya Y; Fuse H; Masai M
Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
[TBL] [Abstract][Full Text] [Related]
18. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
19. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
